HOME ·

07630.HK

IMPACT THERAP-B (07630.HK): Nominates IMP2794 as preclinical candidate compound, first KAT6A-specific PROTAC from self-owned targeted protein degradation platform
Tags：
IMPACT THERAP-B07630.HKR&D Progress
2026-08-12
IMPACT Therapeutics, Inc (07630.HK): Expected H1 Revenue Growth of 276%–359% and Loss Narrowing by 22%–37%
Tags：
IMPACT Therapeutics, Inc07630.HK
2026-08-11
IMPACT THERAP-B (07630.HK): H1 Revenue Expected to Surge 276% to 359% with Loss Narrowing 22% to 37%, Driven by Senaparib's NRDL Inclusion
Tags：
IMPACT THERAP-B07630.HKloss narrowed
2026-08-11
IMPACT Therapeutics(07630.HK): IMP3201 Nominated as Preclinical Candidate Compound, a Dual-Loaded ADC Targeting CEACAM5
Tags：
IMPACT Therapeutics07630.HK
2026-07-27
IMPACT THERAP-B (07630.HK): Clinical Data of Senaparib, IMP1734 and IMP1707 Accepted for Poster Presentations at ESMO Congress 2026
Tags：
IMPACT THERAP-B07630.HKposter presentation
2026-07-20